Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art
- 27 June 2022
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 36 (4) , 865-878
Abstract
No abstract availableKeywords
Funding Information
- Fondazione Telethon
This publication has 57 references indexed in Scilit:
- Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic LeukodystrophyScience, 2013
- Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyJournal of Clinical Investigation, 2013
- A highly secreted sulphamidase engineered to cross the blood‐brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIAEMBO Molecular Medicine, 2013
- Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8Human Gene Therapy, 2012
- Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantationProceedings of the National Academy of Sciences, 2012
- Liver Production of Sulfamidase Reverses Peripheral and Ameliorates CNS Pathology in Mucopolysaccharidosis IIIA MiceMolecular Therapy, 2012
- Therapy for the mucopolysaccharidosesRheumatology, 2011
- Overview of the mucopolysaccharidosesRheumatology, 2011
- Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene TransferMolecular Therapy, 2011
- Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H)Journal of Inherited Metabolic Disease, 2011